Overview

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1 open-label study evaluating the safety of ABT-263 when combined with a standard and weekly regimen of docetaxel in subjects who have solid tumors with measurable disease.

Phase:

Phase 1

Details

Lead Sponsor:

Abbott

Collaborator:

Genentech, Inc.

Treatments:

Docetaxel
Navitoclax